Cargando…

Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein

BACKGROUND: The membrane-proximal external region (MPER) of HIV-1 gp41 is particularly conserved and target for the potent broadly neutralizing monoclonal antibodies (bnMAbs) 2F5, 4E10 and 10E8. Epitope focusing and stabilization present promising strategies to enhance the quality of immune response...

Descripción completa

Detalles Bibliográficos
Autores principales: Benen, Thomas D, Tonks, Paul, Kliche, Alexander, Kapzan, Ruth, Heeney, Jonathan L, Wagner, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256929/
https://www.ncbi.nlm.nih.gov/pubmed/25160824
http://dx.doi.org/10.1186/s12929-014-0079-x
_version_ 1782347651000303616
author Benen, Thomas D
Tonks, Paul
Kliche, Alexander
Kapzan, Ruth
Heeney, Jonathan L
Wagner, Ralf
author_facet Benen, Thomas D
Tonks, Paul
Kliche, Alexander
Kapzan, Ruth
Heeney, Jonathan L
Wagner, Ralf
author_sort Benen, Thomas D
collection PubMed
description BACKGROUND: The membrane-proximal external region (MPER) of HIV-1 gp41 is particularly conserved and target for the potent broadly neutralizing monoclonal antibodies (bnMAbs) 2F5, 4E10 and 10E8. Epitope focusing and stabilization present promising strategies to enhance the quality of immune responses to specific epitopes. RESULTS: The aim of this work was to design and evaluate novel immunogens based on the gp41 MPER with the potential to elicit cross-clade neutralizing antibodies. For that purpose, gp41 was truncated N-terminally in order to dispose immunodominant, non-neutralizing sites and enhance the exposure of conserved regions. To stabilize a trimeric conformation, heterologous GCN4 and HA2 zipper domains were fused based on an in silico “best-fit” model to the protein’s amino terminus. Cell surface exposure of resulting proteins and their selective binding to bnMAbs 2F5 and 4E10 could be shown by cytometric analyses. Incorporation into VLPs and preservation of antigenic structures were verified by electron microscopy, and the oligomeric state was successfully stabilized by zipper domains. These gp41 immunogens were evaluated for antigenicity in an immunization study in rabbits primed with homologous DNA expression plasmids and boosted with virus-like particle (VLP) proteins. Low titers of anti-MPER antibodies were measured by IgG ELISA, and low neutralizing activity could be detected against a clade C and B viral isolate in sera. CONCLUSIONS: Thus, although neutralizing titers were very moderate, induction of cross-clade neutralizing antibodies seems possible following immunization with MPER-focusing immunogens. However, further refinement of MPER presentation and immunogenicity is clearly needed to induce substantial neutralization responses to these epitopes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12929-014-0079-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4256929
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42569292014-12-06 Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein Benen, Thomas D Tonks, Paul Kliche, Alexander Kapzan, Ruth Heeney, Jonathan L Wagner, Ralf J Biomed Sci Research BACKGROUND: The membrane-proximal external region (MPER) of HIV-1 gp41 is particularly conserved and target for the potent broadly neutralizing monoclonal antibodies (bnMAbs) 2F5, 4E10 and 10E8. Epitope focusing and stabilization present promising strategies to enhance the quality of immune responses to specific epitopes. RESULTS: The aim of this work was to design and evaluate novel immunogens based on the gp41 MPER with the potential to elicit cross-clade neutralizing antibodies. For that purpose, gp41 was truncated N-terminally in order to dispose immunodominant, non-neutralizing sites and enhance the exposure of conserved regions. To stabilize a trimeric conformation, heterologous GCN4 and HA2 zipper domains were fused based on an in silico “best-fit” model to the protein’s amino terminus. Cell surface exposure of resulting proteins and their selective binding to bnMAbs 2F5 and 4E10 could be shown by cytometric analyses. Incorporation into VLPs and preservation of antigenic structures were verified by electron microscopy, and the oligomeric state was successfully stabilized by zipper domains. These gp41 immunogens were evaluated for antigenicity in an immunization study in rabbits primed with homologous DNA expression plasmids and boosted with virus-like particle (VLP) proteins. Low titers of anti-MPER antibodies were measured by IgG ELISA, and low neutralizing activity could be detected against a clade C and B viral isolate in sera. CONCLUSIONS: Thus, although neutralizing titers were very moderate, induction of cross-clade neutralizing antibodies seems possible following immunization with MPER-focusing immunogens. However, further refinement of MPER presentation and immunogenicity is clearly needed to induce substantial neutralization responses to these epitopes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12929-014-0079-x) contains supplementary material, which is available to authorized users. BioMed Central 2014-08-27 /pmc/articles/PMC4256929/ /pubmed/25160824 http://dx.doi.org/10.1186/s12929-014-0079-x Text en © Benen et al.; licensee BioMed Central 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Benen, Thomas D
Tonks, Paul
Kliche, Alexander
Kapzan, Ruth
Heeney, Jonathan L
Wagner, Ralf
Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
title Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
title_full Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
title_fullStr Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
title_full_unstemmed Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
title_short Development and immunological assessment of VLP-based immunogens exposing the membrane-proximal region of the HIV-1 gp41 protein
title_sort development and immunological assessment of vlp-based immunogens exposing the membrane-proximal region of the hiv-1 gp41 protein
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256929/
https://www.ncbi.nlm.nih.gov/pubmed/25160824
http://dx.doi.org/10.1186/s12929-014-0079-x
work_keys_str_mv AT benenthomasd developmentandimmunologicalassessmentofvlpbasedimmunogensexposingthemembraneproximalregionofthehiv1gp41protein
AT tonkspaul developmentandimmunologicalassessmentofvlpbasedimmunogensexposingthemembraneproximalregionofthehiv1gp41protein
AT klichealexander developmentandimmunologicalassessmentofvlpbasedimmunogensexposingthemembraneproximalregionofthehiv1gp41protein
AT kapzanruth developmentandimmunologicalassessmentofvlpbasedimmunogensexposingthemembraneproximalregionofthehiv1gp41protein
AT heeneyjonathanl developmentandimmunologicalassessmentofvlpbasedimmunogensexposingthemembraneproximalregionofthehiv1gp41protein
AT wagnerralf developmentandimmunologicalassessmentofvlpbasedimmunogensexposingthemembraneproximalregionofthehiv1gp41protein